共 95 条
[1]
O’Dwyer PJ(1985)Etoposide (VP-16-213): current status of an active anticancer drug N Engl J Med 312 692-700
[2]
Leyland-Jones B(2002)Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer New Engl J Med 346 85-91
[3]
Alonso MT(2007)Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 Br J Cancer 97 162-169
[4]
Noda K(1984)The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 2 1281-1288
[5]
Nishiwaki Y(1987)Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 5 756-767
[6]
Kawahara M(2004)Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228-237
[7]
Okamoto H(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266
[8]
Watanabe K(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563
[9]
Kunikane H(1989)Etoposide: an update Clin Pharm 8 274-293
[10]
Hryniuk W(1986)Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function Cancer Res 46 2566-2571